Neutralization and infectivity characteristics of envelope glycoproteins from human immunodeficiency virus type 1 infected donors whose sera exhibit broadly cross-reactive neutralizing activity

被引:22
作者
Cham, F
Zhang, PF
Heyndrickx, L
Bouma, P
Zhong, P
Katinger, H
Robinson, J
van der Groen, G
Quinnan, GV
机构
[1] Uniformed Serv Univ Hlth Sci, Dept Prevent Med & Biometr, Bethesda, MD 20814 USA
[2] Inst Trop Med, B-2000 Antwerp, Belgium
[3] Univ Life Sci, Inst Appl Microbiol, Vienna, Austria
[4] Tulane Univ, Dept Pediat, New Orleans, LA 70112 USA
[5] New York Vet Adm Med Ctr, New York, NY USA
关键词
HIV-1 envelope glycoprotein; pseudovirions; neutralization; membrane proximal epitope region;
D O I
10.1016/j.virol.2005.11.019
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
In this study, we tested the hypothesis that donors with broadly cross-reactive HIV-1 neutralizing (BCN) sera are infected with viruses encoding envelope glycoproteins (Envs) with unusual immunogenic properties. Cloned env genes were from samples of donors previously identified as having BCN antibodies (BCN donors) and from other donors not known to have such antibodies (non-BCN donors). Neutralization properties of viruses pseudotyped with BCN and non-BCN Envs were determined using BCN, non-BCN sera and broadly cross-neutralizing monoclonal antibodies (Mabs). BCN sera neutralized with higher frequency and geometric mean titers than non-BCN sera. Viruses pseudotyped with BCN Envs were mostly resistant to neutralization by anti-gp120 Mabs but tended to be more sensitive to the anti-gp41 Mabs, 2F5 and 4E10 than non-BCN Env-pseudotyped viruses. Sequence analysis of clones obtained from sequential samples of two BCN donors revealed respective 2F5 epitope mutations T662A and K665T. The K665T mutation evolved as the predominant genotype in the respective donor, consistent with an escape mutation event. The A662T mutation reduced sensitivity to 4E10, as well as 2175 and homologous sera, consistent with neutralization escape mutation and targeting of the 2F5 epitope region by the serum. Our study suggests that viruses infecting these BCN donors encoded Envs that may have been unusually competent for induction of antibodies against the membrane proximal epitope region (MPER) of gp41, and these Envs may be useful vaccine components. (C) 2005 Elsevier Inc. All rights reserved.
引用
收藏
页码:36 / 51
页数:16
相关论文
共 89 条
  • [1] Structural analysis of the epitope of the Anti-HIV antibody 2F5 sheds light into its mechanism of neutralization and HIV fusion
    Barbato, G
    Bianchi, E
    Ingallinella, P
    Hurni, WH
    Miller, MD
    Cilibertol, G
    Cortese, R
    Bazzo, R
    Shiver, JW
    Pessi, A
    [J]. JOURNAL OF MOLECULAR BIOLOGY, 2003, 330 (05) : 1101 - 1115
  • [2] Increased sensitivity to CD4 binding site-directed neutralization following in vitro propagation on primary lymphocytes of a neutralization-resistant human immunodeficiency virus IIIB strain isolated from an accidentally infected laboratory worker
    Beaumont, T
    Quakkelaar, E
    van Nuenen, A
    Pantophlet, R
    Schuitemaker, H
    [J]. JOURNAL OF VIROLOGY, 2004, 78 (11) : 5651 - 5657
  • [3] Potent broad cross-neutralizing sera inhibit attachment of primary HIV-1 isolates (groups M and O) to peripheral blood mononuclear cells
    Beirnaert, E
    De Zutter, S
    Janssens, W
    van der Groen, G
    [J]. VIROLOGY, 2001, 281 (02) : 305 - 314
  • [4] Beirnaert E, 2000, J MED VIROL, V62, P14, DOI 10.1002/1096-9071(200009)62:1&lt
  • [5] 14::AID-JMV3&gt
  • [6] 3.0.CO
  • [7] 2-L
  • [8] Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies
    Binley, JA
    Wrin, T
    Korber, B
    Zwick, MB
    Wang, M
    Chappey, C
    Stiegler, G
    Kunert, R
    Zolla-Pazner, S
    Katinger, H
    Petropoulos, CJ
    Burton, DR
    [J]. JOURNAL OF VIROLOGY, 2004, 78 (23) : 13232 - 13252
  • [9] EFFICIENT NEUTRALIZATION OF PRIMARY ISOLATES OF HIV-1 BY A RECOMBINANT HUMAN MONOCLONAL-ANTIBODY
    BURTON, DR
    PYATI, J
    KODURI, R
    SHARP, SJ
    THORNTON, GB
    PARREN, PWHI
    SAWYER, LSW
    HENDRY, RM
    DUNLOP, N
    NARA, PL
    LAMACCHIA, M
    GARRATTY, E
    STIEHM, ER
    BRYSON, YJ
    CAO, YZ
    MOORE, JP
    HO, DD
    BARBAS, CF
    [J]. SCIENCE, 1994, 266 (5187) : 1024 - 1027
  • [10] Public health - A sound rationale needed for phase IIIHIV-1 vaccine trials
    Burton, DR
    Desrosiers, RC
    Doms, RW
    Feinberg, MB
    Gallo, RC
    Hahn, B
    Hoxie, JA
    Hunter, E
    Korber, B
    Landay, A
    Lederman, MM
    Lieberman, J
    McCune, JM
    Moore, JP
    Nathanson, N
    Picker, L
    Richman, D
    Rinaldo, C
    Stevenson, M
    Watkins, DI
    Wolinsky, SM
    Zack, JA
    [J]. SCIENCE, 2004, 303 (5656) : 316 - 316